Oct 25 2014
BSD Medical Corporation, a leading provider of medical systems that treat cancer and benign diseases using heat therapy, announced today that Drs. JY Gaubert, P Chevallier, and V Vidal, leading French researchers, presented the successful results of their animal study utilizing the MicroThermX®Microwave Ablation System (MicroThermX) at CIRSE 2014.
The study was sponsored by Terumo Europe N.V. The objective of the study was to determine reproducibility of the ablation volumes in liver and lung animal studies using the MicroThermX. The researchers examined the results of 18 liver ablations and 24 lung ablations and concluded that ablation volumes generated with the MicroThermX were reproducible in in-vivo liver and lung tissues.
“The positive results of this study reflect BSD’s and Terumo Europe N.V.’s ongoing, long-term commitment to drive innovation and expand treatment options for patients,” said Sam Maravich, Vice President of International Sales and Marketing at BSD Medical. “This study, and others to follow, could help pave the way for our MicroThermX system to be adopted by hospitals and treatment centers all over the world. Microwave ablation therapy has the potential to improve treatment outcomes and quality of life for patients.”
The study, “In vivo experimental evaluation of ablation volumes obtained by microwave in the lung and liver with MicroThermX,” was conducted by the Department of Adult Radiology at Timone University in Marseille, France; the Department of Radiology at University Hospital L’Archet in Nice, France; and the Laboratory of Experimental and Interventional Imagining at Aix-Marseille University, leading research institutions in France.
Source: http://www.bsdmedical.com/